TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

ROSEN, HIGHLY REGARDED INVESTOR COUNSEL, Encourages Cytokinetics, Inc. Investors to Secure Counsel Before Important November 17 Deadline in Securities Class Action – CYTK

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Rosen Law Firm
ROSEN, HIGHLY REGARDED INVESTOR COUNSEL, Encourages Cytokinetics, Inc. Investors to Secure Counsel Before Important November 17 Deadline in Securities Class Action – CYTK

Rosen Law Firm alerts Cytokinetics investors about a securities class action lawsuit regarding potential misleading statements about a New Drug Application timeline and FDA approval process for aficamten.

Insights
MDT   positive

Diversified medical device portfolio, FDA-approved innovative technologies, potential growth from business restructuring, and long-standing dividend track record


CYTK   negative

The lawsuit alleges the company made false or misleading statements about its drug approval timeline and failed to disclose material risks related to its regulatory submission, suggesting potential investor harm